Xepi™ (ozenoxacin) – New drug approval
December 11, 2017 – The FDA approved Ferrer Internacional’s Xepi (ozenoxacin), for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.
Download PDF
